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Background. In this report, we compare the long-
term outcome of pediatric liver transplantation (LTx) 
patients maintained with tacrolimus-based and with 
cyclosporine (CsA)-based immunosuppressive ther-
apy. We examine long-term patient and graft survival, 
the incidence of rejection, and immunosuppression-
related complications. 
Method. There were 233 consecutive primary L Tx in 
children (ages <18 years) performed between October 
1989 and December 1994 with tacrolimus-based immu-
nosuppressive therapy (Group I). These were com-
pared with 120 consecutive primary LTx performed 
with CsA-based immunosuppressive therapy between 
January 1988 and October 1989(Group II). Children in 
both groups were followed until July 1999. Mean fol-
low-up was 91.41±17.7 months (range 55.6-117.8) for 
Group I, and 128±6.1 months (range 116.7-138.6) for 
Group II. 
Results. At 9 years of follow-up, actuarial patient and 
graft survival were significantly improved (patient 
survival 85.4% in Group I vs. 63.8% in Group II, 
P=O.OOOI; graft survival Group I 78.90/lJ vs. 60.8% Group 
II, P=0.0003) and the rate of re -transplantation was 
significantly lower among patients in Group I (12% in 
Group I vs. 22.5% in Group II P=O.OI). Children in 
Group I also experienced a significantly reduced inci-
dence of acute rejection (0.97 per patient Group I vs. 
1.5 per patient Group II P=0.002) and significantly less 
steroid resistant acute rejection episodes (3.1% in 
Group I vs. 8.6% in Group II P=O.OOOI). 
The mean steroid dose was significantly lower in 
Group I compared with Group II at all time points 
(P=O.OOOl) after LTx. Freedom from steroid was also 
significantly higher in Group I compared with Group 
II at all time points after L Tx (ranging from 78% to 84% 
in Group I and 9% to 32% in Group II during a 1- to 
7-year posttransplant period P=O.OOOl). The rate of 
hypertension was significantly lower in Group I than 
Group II (P=O.OOOI), and the severity of hypertension 
(need for more than one anti-hypertensive medica-
tion) was also significantly lower in Group I than 
Group II (P=O.OOOl). 
Although the rate of posttransplant lymphoprolif-
erative disorder (PTLD) was not significantly differ-
ent (13.7% Group I vs.8.3% Group II, P=0.13), the sur-
vival after PTLD was significantly better for Group I 
at 81.2% than for Group II at 50% after 5 years 
(P=0.034). 
Conclusion. The results suggest that tacrolimus-
based therapy provides significant long-term benefit 
to pediatric L Tx patients, evidenced by significantly 
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improved patient and graft survival, reduced rate of 
rejection, and hypertension with lower steroid doses. 
Critical developmental time points in clinical transplanta-
tion have involved the introduction of immunosuppressive 
agents that significantly improved patient and graft survival 
without incurring serious complications or adverse events 
(1-4). The introduction of cyclosporine A (CsA) to clinical 
transplantation resulted in a dramatic increase in the sur-
vival of various solid organ allografts (5, 6). Expectations 
were further elevated with the introduction tacrolimus in 
1989, initially as rescue therapy for liver allograft recipients 
for whom CsA-based immunosuppressive therapy failed (7-
11). Subsequent success in pilot studies prompted random-
ized clinical trials of tacrolimus vs. CsA; these were followed 
by American and European multi-center randomized studies 
(12-14). On the basis of the results of these trials, tacrolimus 
was approved for clinical use by the Food and Drug Admin-
istration in 1994. 
The use of tacrolimus in pediatric patients has paralleled 
its development in adults. Initial reports by our center dated 
between 1989 and 1991 (7, 15-17) revealed survival and 
toxicity comparable to our previous experience with CsA-
based regimens. Longer follow-up of an expanded population 
of children, reported in 1993, substantiated this experience 
(18). Other pediatric centers have corroborated our findings 
(19-21). 
This is the first report focused on long-term outcome of 
treatment with tacrolimus in pediatric liver transplantation 
(L Tx) patients. Here, we compare our experience with tacroli-
mus and CsA, analyzing the effects on patient and graft 
survival, graft function, causes of death and retransplanta-
tion, long-term immunosuppressive management, and major 
drug-related toxicity. 
PATIENTS AND METHODS 
The results ofLTx in children (ages <18 years) were evaluated in 
a consecutive series of 233 patients maintained with tacrolimus 
(Group I) and 120 consecutive patients maintained with CsA-based 
immunosuppressive therapy (Group II). 
Patients in Group I underwent transplantation between October 
1989 and December 1994. Patients in Group II received liver allo-
grafts between January 1988 and October 1989, just before the 
adoption of tacrolimus-based immunosuppressive therapy. There 
were no significant demographic differences between the groups 
(Table 1). The most frequent indications for LTx among patients in 
both groups were biliary atresia, cryptogenic cirrhosis. and ai-anti-
trypsin deficiency (Table 1). AIl patients were followed until July 
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TABLE 1. Demographics and indications for liver transplantation 
Demographics: Male/female (%) Tacrolimus (group Il: 144189 (61.8/3812) 
Cyciosporin (group Ill: 
59/61 (49.2150.8) 
Mean age (y) 
Age 52 (%) 
Age 2::256 (%) 
Age 2::6 (%) 
Donor age (mean) 
5.1:!: 5.3 
107 (45.90) 
47 (20.2) 
79 (33.9) 
11.1:!: 16.1 
4.6:!: 5.0 
59 (49.1) 
26 (21.7) 
35 (29.2) 
5.8:!: 13.6 
Mean total ischemic time (hr) 13:!: 5.6 12.7:!: 7.1 
Indications Tacrolimus (group 1) (%) Cyclosporin (group II) (%) 
Biliary atresia 
Neonatal hepatitis 
Cryptogenic 
112 (48) 67 (55.8) 
7 (5.8) 
6 (6) 
A-I Antitrypsin deficiency 
Primary liver malignancy 
Acute fulminant failure 
Wilson's disease 
Viral hepatitis 
Drug induced 
Congenital hepatic fibrosis 
Familial cholestasis 
Cystic fibrosis 
Secondary cirrhosis 
Tyrosinemia 
Primary sclerosing cholangitis 
Budd chiari syndrome 
Hamartoma 
5 (2.1) 
36 (15.4) 
16 (6.8) 
6 (2.5) 
5 (2.1) 
6 (2.5) 
5 (2.1) 
3 (1.2) 
8 (3.4) 
7 (3) 
4 (1. 7) 
4 (1.7) 
3 (1.2) 
2 (0.8) 
3 (1.2) 
6 (5) 
5 (4.1) 
4 (3.3) 
3 (2.5) 
3 (2.5) 
3 (2.5) 
1 (0.8) 
2 (1.6) 
2 (1.6) 
2 (1.6) 
2 (1.6) 
2 (1.6) 
1 (0.8) 
1 (0.8) 
Oxalosis 
Other congenital deficiency 
Total 
4 (1. 7) 
4(1.7)0 
233 
3 (2.5)b 
120 
a Crigler Najar syndrome, transcarbamylase deficiency, OTC deficiency, carbamyl phosphate synthetase deficiency. 
b carbamyl phosphate synthetase deficiency, type IV, glycogen storage disease-2. 
1999. The mean follow-up for Group I was 91.41:!:17.7 months (range 
55.7-117.8) and 128:!:6.1 (range 116.7-138.5) for Group II. 
Protocol 
Group I. Until August 1991, tacrolimus was given at a dose of 
0.15 mg/kg/day i.v. After that date, the starting dose was reduced to 
0.075 mg/kg/day i.v. Oral dosing was commenced at 0.1-0.15 mg/kg 
twice daily when bowel function returned to normal. Trough concen-
trations were measured on samples of serum until August 1994 
(ELISA) and subsequently on samples of whole blood concentration 
by TDx assay (Abbott Polyclonal [22-241) at our institution. Target 
trough serum whole blood levels at 1 month. 2-3 months. and >3 
months were 1.0/15, 0.8/12, and 0.7/8-10 ng/ml respectively. 
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FIGURE 1. Patient survival by Kaplan-Meier. 
Group II. CsA at a dose of 4 mg/kg/day was given i.v. until bowel 
function returned to normal, then at 4-10 mg/kg orally twice a day. 
Trough concentrations of CsA were measured on samples of whole 
blood by TDx assay (Abbott [251). Levels were targeted at 1000-1200 
ng/ml in the 1st month, 800-1000 ngiml in the 2nd month. 600-800 
ng/ml in the 3rd month. and 400-600 ng/ml thereafter. 
Both groups of children received 500 mg of hydrocortisone after 
liver allograft reperfusion if the child's body weight was 520 kg, 1000 
mg hydrocortisone if body weight was 2::20 kg, and 1000 mg meth-
ylprednisolone if body weight was >50 kg. 
Children receiving esA were subjected to a steroid taper over 5 
days starting with 0.75 mg/kg of methyl prednisone or the equivalent 
Group I : Tacrolirnus Group II: CsA 
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FIGURE 2. Patient survival for various age groups under tao 
crolimus-based or CsA-based therapy. 
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TABLE 2. Causes of death Group I (n = 233) & Group I (n = 120) 
Mo after Transplantation Total % 
Causes Group Group :0;3 >3",6 >6",12 > 12",24 >24",36 >36",48 >48",60 >60",72 >72",84 >84",96 n Death population 
Bacterial Group I 4 2 1 1 8 23.53 3.43 
Group II 7 7 17.95 5.83 
Fungal Group I 1 1 1 3 8.82 1.29 
Group II 1 1 2 5.13 1.67 
Viral- Group I 1 1 2.94 0.43 
Cytomegalovirus Group II 1 1 2.56 0.83 
Viral-Adeno Group I 1 1 2.94 0.43 
Group II 2 2 5.13 1.67 
Viral-Epstein-Barr Group I 1 1 2 5.88 0.86 
Virus Group II 1 2-lymphoma 1 4 10.26 3.33 
Multiple Infections Group I 1 1 2.94 0.43 
Group II 3 3 7.69 2.50 
Infection (all) Group I (6) (5) (1) (1) (2) (1) (16) (47.06) (6.87) 
Group II (15) (1) (2) (1) (19) (48.72) (15.83) 
Intraoperative Group I 0 0.00 0.00 
Group II 6 6 15.38 5.00 
Central nervous Group I 1 1 2.94 0.43 
system Group II a 0.00 0.00 
Postoperative Group I 3 3 8.82 1.29 
hemorrhage Group II 1 1 2.56 0.83 
Cardiac Group I 3 1 4 11.76 1.72 
Group II 3 3 7.69 2.50 
Respiratory Group I 0 0.00 0.00 
Group II 3 1 1 5 12.82 4.17 
Recurrence of Group I 1 1 2.94 0.43 
malignancy Group II 1 2 3 7.69 2.50 
Primary non- Group I 7 7 20.59 3.00 
function Group II 1 1 2.56 0.83 
Unknown Group I 1 1 2 5.88 0.86 
Group II 1 1 2.56 0.83 
Total n (% death) Group I 21 (61.8) 5 (14.7) 2 (5.9) 1 (2.9) 4 (11.8) 1 (2.9) 0(0) 0(0) 0(0) 0(0) 34 100 14.59 
Group II 29 (74.5) 1 (2.6) 1 (2.6) 3 (7.7) 0(0) 
dose of hydrocortisone every 6 hr on day 1, to 0.6 mglkg every 6 hr on 
day 2, 0.45 mglkg every 6 hr on day 3, 0.3 mglkg every 6 hr on day 4, 
and 0.3 mglkg every 12 hr on day 5. This steroid taper was used only 
after 1993 in Group 1. 
Diagnosis and Treatment of Rejection 
Rejection was diagnosed by liver biochemical profile in the absence 
of any biliary or vascular complication, and confirmed by percutane-
ous liver biopsy. Depending on the severity of rejection and changes 
in liver biochemistry, minimal rejections were treated with an in-
crease in baseline immunosuppressive therapy (CsAltacrolimus) 
and/or prednisone. Mild episodes of rejection were treated with 500 
mg of hydrocortisone in children < 20 kg body weight, 1000 mg 
hydrocortisone in children 20-50 kg, and 1000 mg methylpred-
nisolone in children with body weight> 50 kg. Moderate episodes of 
rejection were treated with an additional steroid taper, consistent 
with the induction taper protocol. Steroid-resistant rejection was 
treated with monoclonal antibody OKT 1 at a dose of 5 ml/day (2.5 ml 
if weight < 20 kg) for 5-7 days in Group I. and for 10-14 days in 
Group II. 
Statistical Analysis 
Actuarial survival was calculated using the Kaplan-Meier statis-
tical method. Differences in survival were calculated using log rank 
analysis. The incidences of various events were compared between 
the two groups using Pearson chi-square. Differences in mean values 
between both groups were compared using the equality of variance 
and independent sample student t test. Statistical Package for Social 
2 (5.1) 1 (2.6) 0(0) 2 (5.1) 0(0) 39 100 32.50 
Sciences 8.0 software (SPSS, Inc., Chicago, IL) was used for gener-
ating the statistical data described above. Multiple time points were 
analyzed to study the statistical significance of differences occurring 
at various times over the follow-up period. A P value of <0.05 was 
considered significant. 
RESULTS 
Patient Survival 
Overall patient survival for both groups is shown in Figure 
1. Nine year actuarial patient survival was 85.4% for Group 
Log rank P = 0.0003 . 
4O"H "Tacrolimus 1---------
20 -H -tr-CsA 
lrl---~---------------
o 6 12 14 36 48 60 n 8-1 96 108 110 
Months Post Transplant 
FiGURE 3. Kaplan-Meier estimates of graft survival. 
P=O.OOO3. 
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I vs. 68.3% in Group II. This difference was statistically 
significant W=O.OOOl). Survival for children s2 years of age 
was inferior to that of children >2 years of age in either 
group. However, the difference did not reach statistical sig-
nificance (P=0.058 Group I; P=O.26 Group II, Figure 2) . 
The majority of deaths occurred within the first 3 months 
after transplantation (Group I 9%; Group 1124%). The most 
frequent causes of death in this period were infection, intra-
operative and postoperative hemorrhage, and primary non-
function of the liver allograft (Table 2). 
Graft Survival 
Retransplantation or deaths without retransplantation 
were considered graft losses. The actuarial graft survival at 9 
years was 78.9% in Group I and 60.8% in Group II (Fig. 3). 
This difference was statistically significant (P=O.0003) . 
Retransplantation 
There were 28 children (12.0%) in Group I and 27 in Group 
II (22.5%) who received a second liver allograft. The differ-
ence in rate of retransplantation was statistically significant 
(P=O.Ol). Of retransplants >80% occurred within the first 3 
months. The most common causes of retransplantation were 
primary nonfunction of the liver allograft and hepatic artery 
thrombosis (Table 3). In addition, one child from Group I 
(0.2%) and six children from Group II (5.0%) received a third 
liver allograft (P=0.007). The survival at 1 and 7 years after 
retransplantation was 57.1% and 53.6% in Group I and 
55.6% and 51.9% in Group II, respectively. The difference 
was not statistically significant (Log rankP=O.97). As shown 
in Figure 4, almost 90% of deaths occurred within the first 3 
months after transplantation. 
Incidence of Rejection 
The overall mean number of rejection episodes per child 
was significantly lower in Group I compared with Group II 
(0.97 vs. 1.5, respectively; P=0.002; Table 4) 
Group l. One hundred children (42.9%) remained rejec-
tion-free. Seventy-three children (31.3%) experienced one ep-
isode of rejection. 38 (16.3%) had 2 episodes, 15 (6.4%) expe-
rienced 3 episodes. 2 (0.8%) had 4 episodes, and 5 (2.1 %) had 
5 episodes 
Group II. Fifty-two children (43.3%) remained rejection-
free. Twenty-five children (20.8%) experienced one episode of 
rejection, 14 (11.7%) experienced 2 episodes, 7 (5.8%) had 3 
! l:~K-____________ _ 
g ~ ~K 60" K--~:ft;;::=;;;:=:-==-=----­
- - --. .-...-.. ~ a. : 
- 010 t-.-----,------------~ I+Gtaoqo11 
~ 10 +-< 1------------
~ i I=-~=-=d=~~l=~ _____ ---~~----o J---: 
Months postretransplant 
FIGURE 4. Incidence of retransplantation (group 1=12%, 
group II =22.5%; P=O.Ol) and survival after retransplantation 
(P=O.97). 
p 
August 27, 2000 JAIN ET AL. 621 
TABLE 4. Incidence of rejection 
Tacrolimus <Group Il 
Episodes of rejection 
No. patients % patients 
0 100 42.9 
1 73 31.3 
2 38 16.3 
3 15 6.4 
4 2 0.8 
5 5 2.1 
Total 233 
Mean rejections per patient 0.97a 
a P value = 0.002 (t test) 
episodes, 9 (7.5%) experienced 4 episodes, and 13 (10.8%) had 
5 episodes. 
Treatment of Rejection 
For children in Group I, 64 episodes of rejection (28.3%) 
were treated simply by an increase in baseline immunosup-
pressive therapy either by increasing the baseline dose of 
tacrolimus (n=19, 8.4%) or increasing the maintenance dose 
of prednisone (n= 14,6.2%), or by increasing the maintenance 
doses of both prednisone and tacrolimus (n=31, 13.7%) with-
out any steroid bolus. There were 156 patients (68.7%) 
treated with i.v. steroid bolus and 7 (3.1%) treated with 
OKT3. 
For children in Group II, 141 episodes of rejection (80.6%) 
were treated with Lv. steroids and 15 (8.6%) were treated 
with OKT3. Nineteen children (10.9%) were converted to 
tacrolimus-based therapy to control steroid-resistant rejec-
tion episodes. The incidence of steroid-resistant rejection re-
quiring OKT3 therapy was significantly lower in tacrolimus-
treated children (Group I) compared with CsS-treated 
children (Group II P=O.OOOI; Table 5). 
Baseline Immunosuppressive therapy 
The mean doses of immunosuppressants and mean trough 
concentrations of tacrolimus and esA are presented in Table 
6. The mean dose of prednisone was 4-8 times lower in 
Group I compared with Group II at various times after trans-
plantation. This difference reached statistical significance 
(P=o.ooon Approximately 50% of children in Group I were 
maintained with a steroid-free immunosuppressive regimen 
by 1 month. At 6-84 months, 80% of children in Group I were 
steroid-free. By contrast, only 6% of children in Group II 
achieved a steroid-free state in the 1st month, and 32% were 
steroid-free at 84 months. The difference was statistically 
significant at all time points analyzed (P=O.OOOl; Figure 5). 
The reduction in tacrolimus dose in 1991 and addition of 
steroid in 1993 did not make any significant difference in 
patient or graft survival. It facilitated the perioperative man-
agement by in decreasing the transient oliguria and or neu-
rological disorder. 
Liver function 
The results of liver function tests at various time intervals 
after transplantation are shown in Table 7 for both groups. 
Mean values approach the normal range at all time points. 
analyzed from 1 month to 8 years after L Tx. 
CsA <Group III 
Total No. patients % patients Total 
episodes episodes 
0 52 43.3 0 
73 25 20.8 25 
76 14 11.7 28 
45 7 5.8 21 
8 9 7.5 31 
25 13 10.8 65 
227 120 175 
1.5a 
Renal Function 
At 1 month after transplantation, mean serum creatinine 
was 0.6 mg/dl and 0.5 mg/dl among children in Group I and 
Group II, respectively. There was little change over 9 years of 
follow up in both groups (Table 7). In Group I, 4 children 
received LTx for oxaloses; 3 of these were undergoing dialysis 
at the time of LTx and received a kidney allograft. Three 
additional children developed end stage renal failure and 
underwent kidney transplantation at 3, 5, and 9 years after 
LTx, respectively. All three children are alive at 7, 4, and 0.5 
years after kidney transplantation, with normal renal and 
liver function. None of the children in Group II developed end 
stage renal failure or required dialysis or kidney transplan-
tation. 
Posttransplant Lymphoproliferative Disorder (PTLD) 
The incidence of PTLD was higher in Group I 
(n=32,13.7%) than in Group II (n=1O, 8.3%); but the dif-
ference was not significant (chi-square P=0.13). However, 
the long-term survival after the diagnosis of PTLD was 
significantly higher among children in Group I compared 
with those in Group II (81.3% vs. 50% at 9 years; P=0.034; 
Fig 6). 
Group I. Thirty-two children (13.7%) developed PTLD af-
ter a mean interval of 11.0 + 12.4 months (range 1.6 - 62.1 
months). The gastrointestinal tract was the most common 
site (n = 14, 43.7%; five of these also had lymph node involve-
ment), followed by lymph nodes (n=8, 25%). Three children 
developed PTLD in the spleen, two in the liver allograft, and 
one each in the tonsil, larynx, and brain. One child had 
Burkitt's lymphoma involving the cervical lymph nodes, and 
another child developed PTLD in multiple sites. Six children 
TABLE 5. Treatment of rejection 
Group I Group II 
Treatment 
n '1> n "'c 
Corticosteroid 156 68.7 141 80.6 
OKT3 7* 3.1 15* 8.6 
Conversion to tacrolimus 0 0 19 10.9 
Increase maintenance CSAltacrolimus 19 8.4 0 0 
Increase maintenance prednisone dose 14 6.2 0 0 
Increase maintenance 31 13.7 0 0 
prednisone + CSAltacrolimus 
Total 227 175 
* P = 0.0001 <Pearson chi square). 
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FIGURE 5. Freedom from corticosteroid use <P=O.OOOl). 
(18.7%) have died after the diagnosis of Pl'LD. Twenty-six 
children (81.3%) are alive and well, 79.5:t15.7 months (range 
44.9 - 107.4) after developing Pl'LD. 
Group II. Ten children (8.3%) developed Pl'LD after a 
mean interval of 35.15:t26.5 months after transplantation 
(range 1.1 - 69.1 months). The most common sites for the 
development ofPTLD were lymph nodes (n=3, 30%) and the 
liver allograft (n=2, 30%; one child also had lymph node 
involvement). The gastrointestinal tract (n=2. 20%), tonsil 
(n=1,10%), and multiple sites (n=l, 10%) were also reported. 
Five children (50.0%) died after the diagnosis ofPTLD, and 5 
children (50.0%) are currently alive 95.4+ 16.9 months (range 
73-108 months) after Pl'LD. 
Hypertension 
Hypertension was defined by the requirement of antihy-
pertensive medications, excluding diuretics, to control hyper-
tension. Overall incidence of hypertension was lower in 
Group I compared with Group II. The percentage of children 
requiring multiple hypertensive medications were also lower 
in Group I compared with Group II. 
In Group I, the incidence of hypertension requiring anti-
hypertensive medications, was 17% at 1 month, declining to 
4% at 6 years. The incidence of hypertension in Group II was 
significantly higher. At 1 month, and 6 years, 60% and 21% 
of children were hypertensive, respectively (P=O.OOOI at all 
time points analyzed; Figure 7). 
The number of children requiring more than one anti-
hypertensive medication varied over time. Of children in 
Group I, 4-20% required multiple anti-hypertensive medica-
tions, whereas 32-53% of children in Group II required sim-
ilar therapy (P=O. 0001; Figure 7). 
Hyperkalemia. In Group I, the incidence of hyperkalemia 
requiring fludrocortisone therapy was 54% at 1 year and 7% 
at 7 years. Hyperkalemia that developed among children in 
Group II was milder and more readily controlled with ion 
exchange resins. 
Diabetes. Currently, all children in both groups are nor-
moglycemic and free of insulin therapy. However, 23.6% of 
children maintained with tacrolimus-based therapy re-
quired insulin for a short time while receiving total paren-
tal nutrition during periods of relatively high corticoste-
roid dosing. 
DISCUSSION 
There are several reports summarizing the advantages of 
tacrolimus over CsA in Ltx 112-14l. Overall, these advan-
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TABLE 7. Liver function and renal function" 
Mo after transplantation 
Liver function Group 
3 6 12 24 36 48 60 72 84 96 
Total bilirubin mg/dl I 0.9 0.5 0.5 0.6 0.6 0.6 0.5 0.6 0.6 0.5 0.7 
II 1.3 1.5 0.7 1.1 1 0.8 0.9 0.7 0.9 0.8 0.8 
AST> UIL I 79 124 66 61 56.5 45 57 50 58 75 33 
II 51 44 46 44 57 56 82 52 58 44 49 
ALTUIL I 66 73 63 60 51 48 49 48 56 39 38 
II 46 51 46 41 49 51 59 53 48 43 51 
Alk-P04 UIL I 229 361 372 350 267 259 249 237 235 340 243 
II 206 205 244 289 233 236 235 281 212 246 241 
GGTPUIL I 142 102 65 54 61 50 55 48 72 58 32 
II 165 123 113 67 65 61 91 51 73 58 103 
Renal function Group 
BUN mg/dl I 18 20 19 18 17 17 16 15 15 14 14 
II 24 23 22 19 17 17 17 16 15 17 17 
Creatinine mgll I 0.6 0.5 0.5 0.7 0.8 0.7 0.7 0.6 0.6 0.7 0.8 
II 0.5 0.6 0.6 0.7 0.6 0.7 0.8 0.8 0.7 0.8 0.7 
" In Group II, 3 children with oxalosis were undergoing dialysis before Ltx received a kidney transplant, and 3 children who went on to 
end stage renal failure after L Tx received a kidney transplant. 
bAST, aspartate amino transferase; ALT, alanine amino transferase; AIK Po4, alkaline phosphatase; GGTP, Gamma glutamyl trans-
ferase. 
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P=nsl/and survival after PTLD significantly better in Group 
I (P=O.034l. 
tages are more pronounced for the pediatric population. Spe-
cifically, both the reduced incidence of steroid-resistant re-
jection and bile-independent absorption properties of 
tacrolimus have been cited as particular short-term benefits 
in the treatment of pediatric patients (18-21,26-28). How-
ever, with introduction of the microemulsion formulation of 
CsA, these kinetics advantages may be ofless value (29, 30). 
There are few reports that compare the long-term outcome of 
pediatric liver transplantation with tacrolimus-based and 
CsA-based therapies (31l. 
The present study reveals significantly improved patient 
and graft survival with tacrolimus-based therapy after 9 
years of follow-up. The data are supported by a significantly 
reduced rate of retransplantation among tacrolimus-treated 
patients. These beneficial effects oftacrolimus may in part be 
related to the advantage of significantly reduced need of 
steroid. The majority of graft loss and death has occurred 
early on in the first 3 months after transplantation. In the 
past. we have reported that reduction in mortality and graft 
loss with tacrolimus, in 4-years of follow-up, was found to be 
related to uncontrolled rejection. sepsis. and technical failure 
by regression analysis (32). 
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FIGURE 7. Incidence of hypertension (P=O.OOOl) and require-
ment for > 1 antihypertensive agent (P=O.OOOl). 
Despite improvement in the surgical technique and better 
postoperative management, early mortality and graft failure 
in the first 3 months has remained troubling, particularly for 
children <2 years of age, regardless of treatment regimen. 
The incidence of late death or late graft loss reported here is 
low when compared with findings in adult populations in 
which age-related disease. de novo cancer, and recurrence of 
viral hepatitis have been major concerns after successful 
liver transplantation (33). 
Although Cao et al. reported a reduced incidence and se-
verity of rejection episodes in patients maintained with ta-
crolimus therapy (31), Andrew et a1. did not observe any 
difference in severity or rate of rejection between tacrolimus-
based or CsA-based therapies in pediatric populations (3l. 
The present results suggest that the improved survival seen 
among tacrolimus-treated patients may be related to a re-
duced requirement to treat severe acute rejection episodes 
with OKT3. Almost 30% of acute episodes were controlled by 
~ : 
i : 
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increasing the baseline maintenance doses of either tacroli-
mus or prednisone (or both). In contrast, with esA-based 
therapy, the addition of an additional steroid bolus was sig-
nificantly higher. As reported for adults (12-14) the rate of 
steroid-resistant rejection requiring OKT3 in patients under-
going CsA-based therapy is significantly higher in children. 
The present results also corroborate several reports of re-
duced requirement for baseline maintenance of corticosteroid 
therapy among tacrolimus-treated patients. Of tacrolimus-
treated children, 70-80% were maintained with mono-
therapy without corticosteroids beyond 6 months after trans-
plantation. This served as the litmus test for the 
development of immunosuppressive weaning trials, which 
eventually resulted in the withdrawal of drug therapy from 
some patient's (34). 
The principal advantage of mono therapy for the pediatric 
population has been normal growth and development. This, 
together with the absence of hirsutism and cushingoid faces, 
has promoted improvements in quality of life (1, 35, 36) 
An additional corollary benefit of the reduced corticoste-
roid requirement may be seen in the reduced incidence of 
hypertension among tacrolimus-treated patients. The long-
term incidence and severity of hypertension was significantly 
lower with tacrolimus-based than with esA-based therapy; oth-
ers have observed this (4). More important, the requirement for 
more than one anti-hypertensive medication was significantly 
lower with tacrolimus at all time points analyzed. 
The rate of development of PI'LD with tacrolimus-based 
therapy in this study population was numerically higher 
than that after treatment with esA. However, the difference 
did not reach statistical significance when compared with the 
number of children at risk 1 month after L Tx. At the same 
time, a higher rate of PI'LD in the pediatric population has 
been reported by others (31). Survival after PI'LD was sig-
nificantly improved with tacrolimus-based compared with 
esA-based therapy. Mortality related to PI'LD was <20% 
after 9 years of follow-up with tacrolimus-based versus 50% 
with CsA-based therapy. PI'LD in Group II occurring with 
relatively high doses of steroid may in part have affected the 
adverse outcome. Since reducing the induction dosage of 
tacrolimus after 1991and in subsequent years, the rate of 
PTLD has been lower, as previously reported (37). Currently, 
the ability to identify children at high risk for PI'LD has 
allowed for appropriate dosing of immunosuppressants in the 
peri transplant period. Recommendations have been made to 
identify Epstein-Barr virus seronegative pediatric liver allo-
graft candidates and the use of polymerase chain reaction to 
monitor viral load in guiding long-term adjustments of im-
munosuppressive and antiviral therapies (4). These practices 
are expected to further reduce the incidence of PTLD as well 
as the mortality resulting from PTLD. 
The incidence of hyperkalemia requiring fludrocortisone 
was higher in tacrolimus patients, but diminished over the 
course of follow-up. Progressive nephrotoxicity leading to end 
stage renal failure has been low in both groups of children, 
with mean serum creatinine remaining stable into adult-
hood. Tacrolimus-associated diabetes has been acceptable 
among both pediatric and adult populations (32, 34, 35). 
In conclusion, our experience has revealed that tacrolimus-
based therapy offers better long-term graft and patient sur-
vival. a higher rate of freedom from steroids. fewer steroid-
resistant rejections. and less hypertension. There were fewer 
deaths attributed to the development of PTLD among tacroli-
mus-treated pediatric liver allograft recipients. Furthermore, 
tacrolimus-treated patients experienced no gum hyperplasia, 
hirsutism, or cushingoid faces. On the basis of this report, 
tacrolimus should constitute the first line of immunosuppres-
sive therapy for primary liver transplantation in children. 
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PRE-EMPTIVE TRANSPLANTS FOR PATIENTS WITH 
RENAL FAILURE 
AN ARGUMENT AGAINST WAITING UNTIL DIALYSIS 
VASSILIOS E. PAPALOIS,l ADYR Moss,l KRISTEN J. GILLINGHAM,! DAVID E.R. SUTHERLAND,l 
ARTHUR J. MATAS,l AND ABHINAV HUMAR1.2 
Background. Pre-emptive kidney transplants have 
not been favored in some centers because of concern 
about possible increased noncompliance and allegedly 
i.nferior long. term results. We analyzed our experience 
with pre-emptive kidney transplants to determine 
whether such concerns are justified. 
Patients and Methods. Between January 1, 1984, and 
June 30, 1998, we performed 1849 adult primary kid-
t Department of Surgery. 
2 Address correspondence to: Abhinav Humar. M.D .• Department 
of Surgery, University of Minnesota. Mayo Mail Code 195. 420 Del-
aware Street SE. Minneapolis. MN 55455. humar001@tc.umn.edu. 
Department of Surgery, University of Minnesota. Minneapolis 55455 
ney transplants: 385 pre-emptive (recipients not un-
dergoing dialysis, ND) and 1464 non-pre-emptive (re-
cipients undergoing dialysis, D). Results were 
subdivided by donor source: cadaver (CAD) and living 
donor (LD). ND recipients tended to be younger, but 
otherwise, the two groups were similar. Posttrans-
plantation quality of life in recipients was evaluated 
using the nationally standardized Short Form Health 
Survey (SF-36). The posttransplantation employment 
status of the recipients was also evaluated. 
Results. The patient survival rate 5 years posttrans-
plantation was significantly better for ND (vs. D) re-
cipients for both CAD (92.6% vs. 76.6%, P=O.OOl) and 
